Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed, HER2-negative adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.~* ECOG performance status of 0 or 1~* For women of childbearing potential, use of an acceptable and effective method of non-hormonal contraception~* For patients who have received recent radiotherapy, recovery prior to randomization from any significant acute toxicity, and radiation treatments have to be completed more than 3 weeks from randomization~Exclusion Criteria:~Disease-Specific Exclusions:~* HER2-positive status~* Prior chemotherapy for locally recurrent or metastatic disease~* Prior hormonal therapy \< 2 weeks prior to randomization~* Prior adjuvant or neo-adjuvant chemotherapy is allowed, provided its conclusion has been for at least 12 months prior to randomization~* Investigational therapy within 28 days of randomization~General Medical Exclusions:~* Life expectancy of \< 12 weeks~* Inadequate organ function~* Uncontrolled serious medical or psychiatric illness~* Active infection requiring intravenous (IV) antibiotics at screening~* Pregnancy or lactation~* History of other malignancies within 5 years prior to screening, except for tumors with a negligible risk for metastasis or death

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Paclitaxel + Bevacizumab \[Avastin\]
- B (Type: EXPERIMENTAL): Paclitaxel + Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).